Longer-term follow up of a phase 1 study of ponatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.
Moshe Talpaz
Consultant or Advisory Role - ARIAD; Novartis
Honoraria - ARIAD
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Hagop M. Kantarjian
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Neil P. Shah
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb
Research Funding - ARIAD; Bristol-Myers Squibb
Dale L. Bixby
Honoraria - ARIAD
Ian Flinn
Research Funding - ARIAD
Thomas O'Hare
No relevant relationships to disclose
Simin Hu
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Victor M. Rivera
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Tim Clackson
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Christopher D. Turner
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Frank G. Haluska
Employment or Leadership Position - ARIAD
Consultant or Advisory Role - ARIAD
Stock Ownership - ARIAD
Research Funding - ARIAD
Brian J Drucker
Consultant or Advisory Role - Ambit BioSciences; AstraZeneca; Avalon Pharma; Bioexpertise; Blueprint Medicines; Calistoga Pharmaceuticals; Cell Therapeutics; Cylene; Geron; Gilead Sciences; kereos; Lilly; Lorus; Millennium; Nodality; Prolexys; Roche; SGX; UCB
Stock Ownership - Blueprint Medicines; MolecularMD
Honoraria - Agios; GlaxoSmithKline; Pfizer
Research Funding - Bristol-Myers Squibb; Novartis
Other Remuneration - ARIAD; Bristol-Myers Squibb; MolecularMD; Novartis
Michael W.N. Deininger
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Incyte; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Incyte; Novartis
Research Funding - Bristol-Myers Squibb; Celgene; Genzyme; Novartis; YM BioSciences
Michael J. Mauro
Consultant or Advisory Role - ARIAD